Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 cabazitaxel/prednisone ± custirsen in second-line metastatic castration-resistant prostate cancer
2012-001461-32Phase 3Completed
- Sponsor
- Achieve Life Sciences
- Start
- May 2012
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of custirsen in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Achieve Life Sciences. Primary endpoint: Overall survival. Started May 2012; status: completed.
02
Drugs
custirsen
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2012-001461-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001461-32.